Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
112
datasets available to search
ShareScore release 0.9.0
Dataset results
112 results for “Contrast agent”
HexafluOride, a Contrast Agent for Placenta Echo-angiography
ClinicalTrials.gov study NCT02884297. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients
ClinicalTrials.gov study NCT02946203. IPD Sharing: NO. Countries: 1. Publications: 6.
Assessment of Indocyanine Green as a Near-Infrared Fluorescent Contrast Agent for Image-guided Liver Surgery
ClinicalTrials.gov study NCT01738217. IPD Sharing: Not stated. Countries: 1. Publications: 14.
Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease
ClinicalTrials.gov study NCT02986932. IPD Sharing: NO. Countries: 1. Publications: 1.
Comparison of Image Quality of Coronary Computed Tomography Angiography bEtweeN High concenTRATion and Low concEntration Contrast Agents(CONCENTRATE Trial)
ClinicalTrials.gov study NCT02549794. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
ClinicalTrials.gov study NCT03173066. IPD Sharing: NO. Countries: 1. Publications: 1.
Negative Oral Contrast Agents Utilization in PET/CT Studies
ClinicalTrials.gov study NCT04577586. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
ClinicalTrials.gov study NCT00827788. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
ClinicalTrials.gov study NCT01260636. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: New MRI contrast agents based on silicon nanotubes loaded with superparamagnetic iron oxide nanoparticles
This article describes the preparation and fundamental properties of a new possible material as a MRI contrast agent based on the incorporation of preformed iron oxide nanocrystals into hollow silicon nanotubes. Specifically, superparamagnetic iron oxide nanoparticles Fe3O4 of two different average sizes (5 nm and 8 nm) were loaded into silicon nanotubes of two different shell thicknesses (40 nm and 70 nm). To achieve proper aqueous solubility, the nanotubes were functionalized with an outer polyethylene glycol (PEG)-diacid (600) moiety via an aminopropyl linkage. Relaxometry parameters r1 and r2 were measured, with the corresponding r2/r1 ratios in PBS confirming the expected negative contrast agent behaviour for these materials. For a given nanocrystal size, the observed r2 values are found to be inversely proportional to nanotube wall thickness, thereby demonstrating the role of nanostructured silicon template on associated relaxometry properties.
Data from: Validation of perfusion quantification with 3D gradient echo dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent in skeletal swine muscle
The purpose of our study was to validate perfusion quantification in a low-perfused tissue by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with shared k-space sampling using a blood pool contrast agent. Perfusion measurements were performed in a total of seven female pigs. An ultrasonic Doppler probe was attached to the right femoral artery to determine total flow in the hind leg musculature. The femoral artery was catheterized for continuous local administration of adenosine to increase blood flow up to four times the baseline level. Three different stable perfusion levels were induced. The MR protocol included a 3D gradient-echo sequence with a temporal resolution of approximately 1.5 seconds. Before each dynamic sequence, static MR images were acquired with flip angles of 5°, 10°, 20°, and 30°. Both static and dynamic images were used to generate relaxation rate and baseline magnetization maps with a flip angle method. 0.1 mL/kg body weight of blood pool contrast medium was injected via a central venous catheter at a flow rate of 5 mL/s. The right hind leg was segmented in 3D into medial, cranial, lateral, and pelvic thigh muscles, lower leg, bones, skin, and fat. The arterial input function (AIF) was measured in the aorta. Perfusion of the different anatomic regions was calculated using a one- and a two-compartment model with delay- and dispersion-corrected AIFs. The F-test for model comparison was used to decide whether to use the results of the one- or two-compartment model fit. Total flow was calculated by integrating volume-weighted perfusion values over the whole measured region. The resulting values of delay, dispersion, blood volume, mean transit time, and flow were all in physiologically and physically reasonable ranges. In 107 of 160 ROIs, the blood signal was separated, using a two-compartment model, into a capillary and an arteriolar signal contribution, decided by the F-test. Overall flow in hind leg muscles, as measured by the ultrasound probe, highly correlated with total flow determined by MRI, R = 0.89 and P = 10−7. Linear regression yielded a slope of 1.2 and a y-axis intercept of 259 mL/min. The mean total volume of the investigated muscle tissue corresponds to an offset perfusion of 4.7mL/(min ⋅ 100cm3). The DCE-MRI technique presented here uses a blood pool contrast medium in combination with a two-compartment tracer kinetic model and allows absolute quantification of low-perfused non-cerebral organs such as muscles.
Contrast solution properties and scan parameters influence the apparent diffusivity of computed tomography contrast agents in articular cartilage
<p>The inability to detect early degenerative changes to the articular cartilage surface that commonly precede bulk osteoarthritic degradation is an obstacle to early disease detection for research or clinical diagnosis. Leveraging a known artifact that blurs tissue boundaries in clinical arthrograms, contrast agent diffusivity can be derived from computed tomography arthrography (CTa) scans. We combined experimental and computational approaches to study protocol variations that may alter the CTa-derived apparent diffusivity. In experimental studies on bovine cartilage explants, we examined how contrast agent dilution and transport direction (absorption vs. desorption) influence the apparent diffusivity of untreated and enzymatically digested cartilage. Using multiphysics simulations, we examined mechanisms underlying experimental observations and the effects of image resolution, scan interval and early scan termination. The apparent diffusivity during absorption decreased with increasing contrast agent concentration by an amount similar to the increase induced by tissue digestion. Models indicated that osmotically induced fluid efflux strongly contributed to the concentration effect. Simulated changes to spatial resolution, scan spacing and total scan time all influenced the apparent diffusivity, indicating the importance of consistent protocols. With careful control of imaging protocols and interpretations guided by transport models, CTa-derived diffusivity offers promise as a biomarker for early degenerative changes.</p>
Metabolic contrast agent produced from transported solid 13C-glucose hyperpolarized via Dynamic Nuclear Polarization
<p>Magnetic Resonance Imaging combined with hyperpolarized <sup>13</sup>C-labelled metabolic contrast agents produced via dissolution Dynamic Nuclear Polarization can, non-invasively and in real-time, report on tissue specific aberrant metabolism. However, hyperpolarization equipment is expensive, technically demanding and needs to be installed on-site for the end-user. In this work, we provide a robust methodology that allows remote production of the hyperpolarized <sup>13</sup>C-labelled metabolic contrast agents. The methodology, built on photo-induced thermally labile radicals, allows solid sample extraction from the hyperpolarization equipment and several hours’ lifetime of the <sup>13</sup>C-labelled metabolic contrast agents at appropriate storage/transport conditions. Exemplified with [U-<sup>13</sup>C, d<sub>7</sub>]-D-glucose, we remotely produce hyperpolarized <sup>13</sup>C-labelled metabolic contrast agents and generate above 10,000-fold liquid-state Magnetic Resonance signal enhancement at 9.4 T, keeping on-site only a simple dissolution device.</p>
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditi
ClinicalTrials.gov study NCT04307186. IPD Sharing: NO. Countries: 4. Publications: 0.
High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
ClinicalTrials.gov study NCT05954559. IPD Sharing: YES. Countries: 1. Publications: 0.
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
ClinicalTrials.gov study NCT02142608. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
ClinicalTrials.gov study NCT00395733. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
ClinicalTrials.gov study NCT07110519. IPD Sharing: YES. Countries: 1. Publications: 0.
Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients
ClinicalTrials.gov study NCT01017796. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
ClinicalTrials.gov study NCT02084628. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.